𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Mechanisms of drug resistance in ovarian cancer

✍ Scribed by Steven W. Johnson; Robert F. Ozols; Thomas C. Hamilton

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
669 KB
Volume
71
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Mechanisms and modulation of resistance
Mechanisms and modulation of resistance to chemotherapy in ovarian cancer
✍ Raymond P. Perez; Thomas C. Hamilton; Robert F. Ozols; Robert C. Young 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 1005 KB

Chemotherapy for advanced ovarian cancer remains suboptimal. Despite the improvements in objective response rates realized with cisplatin-based combination chemotherapeutic regimens, most patients still die of refractory cancer. Drug resistance has emerged as the single most important determinant of

Multidrug resistance in ovarian cancer
Multidrug resistance in ovarian cancer
✍ Antonio Fojo; Thomas C. Hamilton; Robert C. Young; Robert F. Ozols 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 687 KB

The development of acquired resistance has limited the effectiveness of chemotherapy in the treatment of ovarian cancer. Experimental model systems were developed to study the mechanisms associated with primary resistance to chemotherapeutic agents and broad cross-resistance (multidrug resistance) w

FAU regulates carboplatin resistance in
FAU regulates carboplatin resistance in ovarian cancer
✍ Esther L. Moss; Mirna Mourtada-Maarabouni; Mark R. Pickard; Charles W. Redman; G 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB

## Abstract The development of chemotherapy resistance by cancer cells is complex, using different mechanisms and pathways. The gene __FAU__ (Finkel‐Biskis‐Reilly murine sarcoma virus (__F__BR‐MuSV)‐__a__ssociated __u__biquitously expressed gene) was identified through functional expression cloning

Class III β-tubulin and the cytoskeletal
Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer
✍ Marta De Donato; Marisa Mariani; Lella Petrella; Enrica Martinelli; Gian Franco 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 498 KB

## Abstract The Class III β‐tubulin isotype (βIII‐tubulin) is a predictive biomarker in ovarian cancer and other solid tumor malignancies. We discovered that βIII‐tubulin function is linked to two GTPases: guanylate‐binding protein 1 (GBP1), which activates its function, and GNAI1, which inhibits i

Molecular profiling of platinum resistan
Molecular profiling of platinum resistant ovarian cancer
✍ Jozien Helleman; Maurice P.H.M. Jansen; Paul N. Span; Iris L. van Staveren; Leon 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 362 KB

## Abstract The aim of this study is to discover a gene set that can predict resistance to platinum‐based chemotherapy in ovarian cancer. The study was performed on 96 primary ovarian adenocarcinoma specimens from 2 hospitals all treated with platinum‐based chemotherapy. In our search for genes, 24

Novel camptothecin derivative BNP1350 in
Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: Determination of efficacy and possible mechanisms of resistance
✍ Annemarie H. van Hattum; Hennie M.M. Schlüper; Frederick H. Hausheer; Herbert M. 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 236 KB 👁 1 views

## Abstract The novel camptothecin derivative BNP1350 (7‐[2‐trimethylsilyl)ethyl]‐20(__S__)‐camptothecin), also known as Karenitecin, has been developed for superior oral bioavailability and increased lactone stability. In our study, we describe the antiproliferative effects of BNP1350, SN‐38 and t